ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
,2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1006 - 1023, http://dx.doi.org/10.1111/jdv.19880
,2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882
,2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038
,2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women's Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125
,2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
,2024, 'Atypical fixed drug eruption in confetti due to paracetamol', Dermatologica Sinica, 42, pp. 160 - 161, http://dx.doi.org/10.4103/ds.DS-D-23-00161
,2024, 'Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.20149
,2024, 'Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT (Advances in Therapy, (2024), 10.1007/s12325-024-02810-3)', Advances in Therapy, http://dx.doi.org/10.1007/s12325-024-02886-x
,2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14308
,2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, http://dx.doi.org/10.1016/j.jid.2024.02.023
,2024, 'Gender equity in academic dermatology: Problems aplenty, yet paths ahead', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.20027
,2023, 'Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: A 30-month experience', Clinical and Experimental Dermatology, 48, pp. 1266 - 1269, http://dx.doi.org/10.1093/ced/llad215
,2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195
,2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182
,2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673
,2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036
,2023, 'Immunisation status during biologic therapy for hidradenitis suppurativa and psoriasis', JEADV Clinical Practice, 2, pp. 549 - 552, http://dx.doi.org/10.1002/jvc2.182
,2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4
,2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487
,2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011
,2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914
,2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', The Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5
,2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljad113.144
,2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108
,2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033
,2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', JAAD International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016
,2023, 'ISID0459 - Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', , http://dx.doi.org/10.26226/m.641999e770c3630019098d8e
,2023, 'ISID0396 - A novel investigator global assessment score for the evaluation of keratosis pilaris', , http://dx.doi.org/10.26226/m.641999e460d56100127c27b2
,2023, 'A review of JAK and IL-23 inhibitors to treat vitiligo', Australasian Journal of Dermatology, 64, pp. 204 - 212, http://dx.doi.org/10.1111/ajd.14001
,2023, 'Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases', Clinical and Experimental Dermatology, 48, pp. 448 - 452, http://dx.doi.org/10.1093/ced/llac137
,2023, 'ISID0390 - Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases.', , http://dx.doi.org/10.26226/m.641999e288811f001400fb3d
,2023, 'Median canaliform nail dystrophy in a 2-year-old boy: Case report and review of the literature', Pediatric Dermatology, 40, pp. 511 - 518, http://dx.doi.org/10.1111/pde.15181
,2023, 'Primary cutaneous amyloidosis: A review of the available studies and gaps in data', Australasian Journal of Dermatology, 64, pp. e121 - e124, http://dx.doi.org/10.1111/ajd.14012
,2023, 'Fibrillar matrix, Echogenicity, Contour, Thickness, and Suture (FECTS) vs. Global: A comparison of 2 scales developed to assess ultrasound images post rotator cuff repair', Journal of Shoulder and Elbow Surgery, 32, pp. 713 - 728, http://dx.doi.org/10.1016/j.jse.2022.10.035
,2023, 'Gender Equity in Medicine and Dermatology in the United States: The Long Road Traveled and the Journey ahead', Dermatologic Clinics, 41, pp. 265 - 278, http://dx.doi.org/10.1016/j.det.2022.08.007
,2023, 'Pemphigus scoring systems and their validation studies – A review of the literature', Dermatologica Sinica, 41, pp. 67 - 77, http://dx.doi.org/10.4103/ds.DS-D-22-00150
,2023, 'Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study', JAAD International, 10, pp. 6 - 13, http://dx.doi.org/10.1016/j.jdin.2022.08.025
,2023, 'The dangers of social media: patients with atopic dermatitis ceasing their basic treatment', Clinical and Experimental Dermatology, 48, pp. 142 - 143, http://dx.doi.org/10.1093/ced/llac056
,2023, 'Eksfolyatif keilit tedavisinde tildrakizumab', Mucosa, 6, pp. 19 - 21, http://dx.doi.org/10.33204/mucosa.1209480
,2023, '307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljac140.007
,2023, 'A life for autoimmune blistering diseases: in memoriam Detlef Zillikens', Frontiers in Immunology, 14, http://dx.doi.org/10.3389/fimmu.2023.1291590
,2023, 'Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1149742
,2023, 'Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1268285
,2023, 'Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study', British Journal of Dermatology, 188, pp. 12 - 21, http://dx.doi.org/10.1093/bjd/ljac001
,2023, 'From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus', JMIR Dermatology, 6, http://dx.doi.org/10.2196/46812
,2023, 'Practice Dilemma: Expanding Melanonychia in the Paediatric Setting', Skin Appendage Disorders, 9, pp. 58 - 60, http://dx.doi.org/10.1159/000526102
,2023, '390 Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases', Journal of Investigative Dermatology, 143, pp. S67 - S67, http://dx.doi.org/10.1016/j.jid.2023.03.396
,2023, '396 A novel investigator global assessment score for the evaluation of keratosis pilaris', Journal of Investigative Dermatology, 143, pp. S68 - S68, http://dx.doi.org/10.1016/j.jid.2023.03.402
,2023, '459 Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', Journal of Investigative Dermatology, 143, pp. S79 - S79, http://dx.doi.org/10.1016/j.jid.2023.03.465
,